Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 23, Issue 23, Pages 3325-3341Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612823666170601101644
Keywords
Polyamines; parasites; Trypanosoma brucei; Trypanosoma cruzi; Leishmania; Plasmodium; therapeutic strategies
Categories
Funding
- National Institute of Allergy and Infectious Disease [AI041622]
- American Heart Association [0950095G]
Ask authors/readers for more resources
There is an urgent need for the identification and validation of new therapeutic targets in protozoan parasites because currently available drugs are limited in number and usefulness, and no vaccines are available. The discovery that alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, is an efficacious treatment for African Sleeping Sickness caused by the protozoan parasite Trypanosoma brucei, has validated the polyamine pathway as a target in protozoan parasites. Polyamines are ubiquitous organic cations that play critical roles in key cellular processes such as growth, differentiation, and macromolecular biosynthesis. In recent years, remarkable progress has been made in the characterization of the polyamine pathway in a variety of protozoan parasites and this review will highlight surprising and unique features that could lead to new therapeutic strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available